Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats

Cancer Biology and Therapy

Volumn 6, Issue 4, 2007, Pages 541-547

  Gibson, Rachel J ^a,b   Stringer, Andrea M ^a,b   Bowen, Joanne M ^b   Logan, Richard M ^b   Yeoh, Ann S J ^a,b   Burns, Jaimi ^a,b   Alvarez, Enrique ^c   Keefe, Dorothy M K ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CURAGEN CORPORATION   (United States)

Author keywords

Diarrhoea; Gastrointestinal mucositis; Irinotecan; Velafermin

Indexed keywords

ATROPINE; FIBROBLAST GROWTH FACTOR; IRINOTECAN; UNCLASSIFIED DRUG; VELAFERMIN;

ARTICLE; CONTROLLED STUDY; DIARRHEA; GASTROINTESTINAL MUCOSA; MUCOSA INFLAMMATION; NONHUMAN; RAT;

EID: 34548282538     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.4.3848     Document Type: Article

References (31)

1. Keefe DM, Gibson RJ, Hauer-Jenson M. Gastrointestinal mucositis. Sem Oncol Nurs 2004; 20:38-47.
2. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47:632-7.
3. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DMK. Irinotecan causes severe small intestinal damage as well as colonic damage in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095-100.
4. Keefe DM. Gastrointestinal mucositis: A new biological model. Support Care Cancer 2004; 12:6-9.
5. Pico JL, Avila-Garavito A, Naccache P. Mucositis: Its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998; 3:446-51.
6. Speilberger RT, Stiff P, Bensinger W, Gentile T, Weisdorf DJ, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, Le Maistre CF. Palifermin for oral mucositis after intensive therapy for hematological malignancies. N Engl J Med 2004; 351:2590-8.
7. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhoea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116:464-70.
8. Sonis ST, Elting LS, Keefe DM, Peterson DE, Schubert MM, Hauer-Jenson M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein E. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995-2025.
9. Rubenstein EB, Peterson DE, Schubert MM, Keefe DM, McGuire DB, Epstein JB, Elting LS, Fox PC, Loprinzi CL, Sonis ST. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100:2026-46.
10. Benson IIIrd AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson Jr JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918-26.
11. Stern J, Ippoliti C. Management of acute cancer treatment-induced diarrhea. Semin Oncol Nurs 2003; 19:11-6.
12. Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL, Sylander ED, Rittman B, Bendele A, Sartor RB, Lichenstein HS. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterol 2002; 123:1151-62.
13. Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, Burgess C, Fernandes E, Rittman B, Shimkets J, LaRochelle WJ, Lichenstein HS. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res 2001; 61:3131-8.
14. Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M, Jeffers M, Dindinger M, Twomlow N, Ghatpande A, LaRochelle WJ, Sonis ST, Lichenstein HS. Pre-clinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 2003; 9:3454-61.
15. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 45:1005-19.
16. Housley RM, Morris CF, Boyle W, Ring B, Blitz R, Tarpley JE, Aukerman SL, Devine PL, Whitehead RH, Pierce GF. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994; 94:1764-77.
17. Han DS, Li F, Holt L, Connolly K, Hubert M, Miceli R, Okoye Z, Santiago G, Windle K, Wong E, Sartor RB. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am J Physiol 2000; 279:G1011-G22.
18. Potten CS, O'Shea JA, Farrell CL, Rex K, Booth C. The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierachy of the crypts of the murine small intestine. Cell Growth Diff 2001; 12:265-75.
19. Dignass A, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: Central role of transforming growth factor β. Gastroenterol 1993; 105:1323-32.
20. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58:933-9.
21. Farrell CL, Rex KL, Chen JN, Bready JV, DiPalma CR, Kaufman SA, Rattan A, Scully S, Lacey DL. The effects of keratinocyte growth factor in pre-clinical models of mucositis. Cell Prolif 2002; 35:78-85.
22. Farrell CL, Rex KL, Kaufman SA, Dipalma CR, Chen JN, Scully S, Lacey DL. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Rad Biol 1999; 75:609-20.
23. Schuster MW, Shore TB, Greenberg J, Jalilizeinali B, Possley S, Halvorsen YD, Annino V, Hahne W. Phase I trial of CG53135-05 to prevent mucositis in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT). J Clin Oncol 2005; 23:6656.
24. Gibson RJ, Keefe DMK, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BE, Cummins AG. The effect of keratinocyte growth factor on tumor growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Can Chem Pharmacol 2002; 50:53-8.
25. Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002; 47:2751-7.
26. Gibson RJ, Bowen JM, Alvarez E, Finnie JW, Keefe DMK. Establishment of a single dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2006, (in press).
27. Sonis ST. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34:39-43.
28. Sonis ST. The pathobiology of mucositis. Nature Reviews Cancer 2004; 4:277-84.
29. Sonis ST. A biological approach to mucositis. J Support Oncol 2004; 2:21-32, (discussion 5-6).
30. Abigerges D, Armand JP, Chabot GG, DaCosta L, Fadel E, Cote C, Heraot P, Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhoea. J Natl Cancer Inst 1994; 86:446-9.
31. Viele CS. Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs 2003; 19:2-5.